TENX - Tenax Therapeutics Inc Stock Price, Fair Value and News

3.65USD+0.02 (+0.55%)Delayed as of 22 Apr 2024, 12:56 pm ET

Market Summary

USD3.65+0.02

Delayedas of 22 Apr 2024, 12:56 pm

0.55%

TENX Stock Price

View Fullscreen

TENX RSI Chart

TENX Valuation

Market Cap

7.1M

Price/Earnings (Trailing)

1.37

Price/Sales (Trailing)

0.51

Price/Free Cashflow

-1.2

TENX Price/Sales (Trailing)

TENX Profitability

Return on Equity

64.18%

Return on Assets

44.48%

Free Cashflow Yield

-83.05%

TENX Fundamentals

TENX Revenue

Revenue (TTM)

13.9M

Rev. Growth (Qtr)

-97.85%

TENX Earnings

Earnings (TTM)

5.2M

Earnings Growth (Yr)

-29.43%

Earnings Growth (Qtr)

191.01%

Breaking Down TENX Revenue

52 Week Range

3.66

(Low)(High)

Last 7 days

-3.7%

Last 30 days

-6.0%

Last 90 days

-62.9%

Trailing 12 Months

-87.4%

How does TENX drawdown profile look like?

TENX Financial Health

Current Ratio

3.26

TENX Investor Care

Buy Backs (1Y)

91.01%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.0M	9.3M	11.6M	13.9M
2015	0	49.3K	4.7M	0
2014	444.9K	263.0K	0	0
2013	1.1M	1.2M	1.1M	625.5K
2012	346.3K	381.1K	593.7K	1.0M
2011	0	104.1K	156.6K	224.7K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tenax Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 21, 2022	rich stuart	gifted	-	-	1,909,580	chief medical officer
Sep 21, 2022	rich stuart	gifted	-	-	-1,909,580	chief medical officer
Aug 11, 2022	doogan declan	gifted	-	-	-567,871	-
Aug 11, 2022	doogan declan	gifted	-	-	567,871	-
Nov 29, 2021	rich stuart	gifted	-	-	1,909,580	chief medical officer
Nov 29, 2021	rich stuart	gifted	-	-	-1,909,580	chief medical officer
Oct 12, 2021	rich stuart	gifted	-	-	1,909,580	chief medical officer
Oct 12, 2021	rich stuart	gifted	-	-	-1,909,580	chief medical officer
Jun 30, 2021	doogan declan	gifted	-	-	-567,871	-
Jun 11, 2021	davidson michael h.	acquired	-	-	512,000	-

Which funds bought or sold TENX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 10, 2024	Banque Cantonale Vaudoise	sold off	-100	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	51,088	51,088	-%
Mar 04, 2024	TUCKER ASSET MANAGEMENT LLC	unchanged	-	-	1.00	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-11,000	-	-%
Feb 14, 2024	STATE STREET CORP	reduced	-0.06	-1,937	26,105	-%
Feb 14, 2024	Lido Advisors, LLC	sold off	-100	-2,990	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-29,014	-	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	20,917	20,917	-%
Feb 14, 2024	LPL Financial LLC	sold off	-100	-5,980	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	39,095	39,095	-%

Are Funds Buying or Selling TENX?

Are funds buying TENX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TENX

No. of Funds

Unveiling Tenax Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 20, 2024	s.h.n. financial investments ltd.	5.6%	107,000	SC 13G
Feb 16, 2024	cvi investments, inc.	9.9%	204,027	SC 13G
Feb 15, 2024	lind global fund ii lp	9.9%	71,500	SC 13G
Feb 14, 2024	armistice capital, llc	0.07%	17,241	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	4,960,728	SC 13G/A
Feb 13, 2023	intracoastal capital, llc	4.99%	479,733	SC 13G
Feb 09, 2023	rich stuart	2.32%	215,303	SC 13D/A
Feb 09, 2023	doogan declan	1.96%	181,894	SC 13D/A
Jan 06, 2023	rich stuart	9.38%	215,303	SC 13D/A
Jan 06, 2023	doogan declan	7.94%	181,894	SC 13D/A

Recent SEC filings of Tenax Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	EFFECT	EFFECT
Apr 12, 2024	EFFECT	EFFECT
Apr 11, 2024	POS AM	POS AM
Apr 11, 2024	POS AM	POS AM
Mar 28, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report
Feb 26, 2024	424B3	Prospectus Filed
Feb 26, 2024	424B3	Prospectus Filed
Feb 23, 2024	8-K	Current Report
Feb 21, 2024	424B3	Prospectus Filed

Peers (Alternatives to Tenax Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Tenax Therapeutics Inc News

Latest updates

Tenax Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2015Q3	2015Q2	2015Q2	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4	2011Q3	2011Q2	2011Q1
Revenue	-0.9%	13,530	13,652	13,774	13,897	11,126	8,355	5,584	2,813	42.00	56.00	166	182	222	515	272	78.00	148	95.00	59.00	43.00	27.00
Gross Profit	-	-	-	-	-	-	-	-	-133	180*	21.00	8.00	37.00	1.00	5.00	6.00	5.00	2.00	17.00	25.00	44.00	27.00
Operating Expenses	57.8%	3,341	2,117	1,236	1,539	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	56.1%	1,642	1,052	1,038	1,274	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	59.4%	1,699	1,066	198	266	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-59.6%	2.00	5.00	9.00	7.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	191.0%	5,739	1,972	-1,106	-1,406	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-99.8%	0.37*	154.00*	173.17*	137.57*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	43.6%	-1,174	-2,082	-924	-1,726	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.7%	11,685	11,889	14,045	15,272	3,405	4,739	8,355	3,738	5,992	8,912	2,885	4,561	6,869	8,997	5,353	5,955	6,365	7,774	9,664	11,457	13,337
Current Assets	-1.7%	11,684	11,883	14,039	15,265	3,208	4,514	8,102	3,456	5,689	8,583	2,532	4,518	6,796	8,897	5,214	5,798	6,181	7,562	9,425	11,191	13,320
Cash Equivalents	-12.1%	9,792	11,141	13,394	14,415	2,124	3,806	7,229	2,869	5,584	8,354	1,671	3,537	6,250	8,236	4,085	4,359	4,906	6,649	8,407	10,322	12,367
Net PPE	-100.0%	-	5.00	6.00	6.00	7.00	10.00	11.00	12.00	7.00	6.00	6.00	5.00	6.00	3.00	4.00	5.00	7.00	8.00	9.00	10.00	9.00
Liabilities	495.6%	3,587	602	824	989	1,912	785	1,572	2,131	1,748	1,673	1,414	1,465	2,243	1,593	2,324	2,536	2,593	1,237	1,044	1,117	1,566
Current Liabilities	495.6%	3,587	602	824	984	1,848	690	1,446	1,976	1,564	1,461	1,175	1,434	2,119	1,379	2,187	2,505	2,532	1,129	938	1,014	1,566
Shareholder's Equity	-28.3%	8,098	11,287	13,222	14,278	1,493	3,954	6,784	1,606	4,245	7,239	1,471	3,096	4,626	7,404	3,029	3,419	3,772	6,537	10,340	10,340	11,772
Retained Earnings	-1.1%	-297,252	-294,027	-292,055	-290,948	-289,542	-286,993	-284,076	-281,215	-278,494	-275,283	-271,484	-269,767	-246,019	-243,190	-240,969	-238,823	-236,168	-233,376	-231,153	-229,391	-227,801
Additional Paid-In Capital	0.0%	305,351	305,311	305,274	305,224	291,035	290,944	290,858	282,819	282,736	282,520	272,954	272,863	250,644	250,592	243,996	242,242	239,940	239,911	239,771	239,729	239,572
Shares Outstanding	-100.0%	-	23,862	23,862	21,777	-	29,980	1,260	1,260	1,260	1,260	1,261	748	12,619	-	-	-	-	-	-	-	-
Float	-	-	-	7,031	-	-	-	5,005	-	-	-	30,559	-	-	-	9,100	-	-	-	9,167	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	43.6%	-1,174	-2,081	-922	-1,724	-1,688	-3,330	-3,431	-2,937	-2,768	-3,021	-1,845	-3,221	-1,987	-2,385	-2,228	-2,671	-1,726	-1,782	-1,914	-2,132	-1,197
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53.00
Cashflow From Investing	-	-	-	2.00	1.00	4.00	-	-	-6.32	-1.70	512	-20.27	-36.96	4.00	3.00	20.00	-6.33	-16.75	24.00	-204*	-8.80	1,311
Cashflow From Financing	-1.9%	-174	-171	-99.91	14,015	2.00	-91.87	7,792	229	-	9,193	-	545	-1.35	6,533	1,935	2,130	-	-	-	97.00	8,907

TENX Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
General and administrative	$ 5,005,135	$ 5,675,231
Research and development	3,228,806	5,377,412
Total operating expenses	8,233,941	11,052,643
Net operating loss	8,233,941	11,052,643
Interest expense	23,967	4,443
Other income, net	(547,235)	(9,191)
Net loss	7,710,673	11,047,895
Total comprehensive loss	$ 7,710,673	$ 11,047,895
Net loss per share, basic and diluted	$ (31.04)	$ (600.71)
Weighted average number of common shares outstanding, basic and diluted	248,447	18,391

TENX Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 9,792,130	$ 2,123,682
Prepaid expenses	1,639,797	738,927
Other current assets	251,583	345,856
Total current assets	11,683,510	3,208,465
Right of use asset	0	179,503
Property and equipment, net	0	7,189
Other assets	1,117	9,552
Total assets	11,684,627	3,404,709
Current liabilities
Accounts payable	2,073,149	448,425
Accrued liabilities	1,012,468	775,045
Note Payable	500,903	624,302
Total current liabilities	3,586,520	1,847,772
Long term liabilities
Lease liability	0	64,196
Total long term liabilities	0	64,196
Total liabilities	3,586,520	1,911,968
Stockholders' equity
Common stock, par value $0.0001 per share; authorized 400,000,000 shares; issued and outstanding 298,281 as of December 31, 2023 and 28,648 as of December 31, 2022	30	3
Additional paid-in capital	305,350,830	291,034,818
Accumulated deficit	(297,252,753)	(289,542,080)
Total stockholders' equity	8,098,107	1,492,741
Total liabilities and stockholders' equity	11,684,627	3,404,709
Series A Preferred Stock [Member]
Stockholders' equity
Preferred stock, undesignated, authorized 4,818,654 shares; See Note E Series A Preferred stock, par value $0.0001, issued 5,181,346 shares; outstanding 210, as of December 31, 2023 and December 31, 2022, respectively	$ 0	$ 0

About Tenax Therapeutics Inc

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

CEO	Mr. Christopher T. Giordano
WEBSITE	tenaxthera.com
INDUSTRY	Biotechnology
EMPLOYEES	7

Tenax Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Tenax Therapeutics Inc? What does TENX stand for in stocks?

TENX is the stock ticker symbol of Tenax Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tenax Therapeutics Inc (TENX)?

As of Fri Apr 19 2024, market cap of Tenax Therapeutics Inc is 7.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TENX stock?

You can check TENX's fair value in chart for subscribers.

What is the fair value of TENX stock?

You can check TENX's fair value in chart for subscribers. The fair value of Tenax Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tenax Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TENX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tenax Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TENX is over valued or under valued. Whether Tenax Therapeutics Inc is cheap or expensive depends on the assumptions which impact Tenax Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TENX.

What is Tenax Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, TENX's PE ratio (Price to Earnings) is 1.37 and Price to Sales (PS) ratio is 0.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TENX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tenax Therapeutics Inc's stock?

In the past 10 years, Tenax Therapeutics Inc has provided -0.659 (multiply by 100 for percentage) rate of return.